ESR1 and breast cancer: CDK4/6 inhibitors such as palbociclib 97, ribociclib 98 and abemaciclib 99 combined with endocrine agents have exhibited significant PFS benefit and are approved by the FDA as the standard treatment for ER+, HER2- advanced BC patients (Figure 1).